Welcome to the Legend Biotech’s First Quarter 2025 Earnings Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer ...

BillionToOne, a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, announces the appointment of Dr. Haywood L. Brown as Chief Medical ...

a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics.

Deb Hart; Head, Investor Relations; Maravai LifeSciences Holdings Inc. William Martin; Chief Executive Officer; Maravai LifeSciences Holdings Inc. Kevin Herde; Chief ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, May 09, 2025 (GLOBE NEWSWIRE) -- The "Collaboration Deals in Biotechnology 2019-2025" report has been added to ResearchAndMarkets.com's offering.

Dublin, May 09, 2025 (GLOBE NEWSWIRE) -- The "Collaboration Deals in Biotechnology 2019-2025" report has been added to ResearchAndMarkets.com's offering. Collaboration Deals in Biotechnology ...

As reported in our April 25, 2025, blog item, the National Security Commission on Emerging Biotechnology (NSCEB) announced on ...

Dublin, May 09, 2025 (GLOBE NEWSWIRE) -- The "Joint Venture Deals in Pharmaceuticals and Biotechnology 2016-2025" report has been added to ResearchAndMarkets.com's offering. Joint Venture Deals in ...

This report provides details of the latest partnering deals which disclose a royalty rate announced in the pharmaceutical, biotechnology, and diagnostic sectors. The initial chapters of this ...

Dublin, May 09, 2025 (GLOBE NEWSWIRE) -- The "Royalty Rates in Pharmaceutical and Biotechnology Deals 2010-2025" has been added to ResearchAndMarkets.com's offering. This report contains a ...

After meeting with Alabama head coach Nick Saban Thursday, President Donald Trump is reportedly considering an executive order to regulate NIL deals in college athletics. According to The Wall ...

With long development timelines and high burn rates, biotech companies must navigate capital markets with precision.